within Pharmacolibrary.Drugs.ATC.C;

model C10AA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.00085,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.086,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.041666666666666664,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.121,
    k12             = 143,
    k21             = 143
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Simvastatin is a lipid-lowering medication of the statin class, used primarily to treat high cholesterol and reduce the risk of cardiovascular disease. It inhibits HMG-CoA reductase, a key enzyme involved in the mevalonate pathway of cholesterol synthesis. Simvastatin is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of simvastatin in healthy adult subjects after single oral dose administration.</p><h4>References</h4><ol><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342090-00003&quot;>10.2165/00003088-200342090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12882588/&quot;>https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Nicolussi, S, et al., &amp; Meyer Zu Schwabedissen, HE (2020). Clinical relevance of St. John&#x27;s wort drug interactions revisited. <i>British journal of pharmacology</i> 177(6) 1212–1226. DOI:<a href=&quot;https://doi.org/10.1111/bph.14936&quot;>10.1111/bph.14936</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31742659/&quot;>https://pubmed.ncbi.nlm.nih.gov/31742659</a></p></li><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AA01;
